The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...

The FDA has approved a generic version of lenalidomide, a drug used to treat multiple myeloma and myelodysplastic syndromes, with availability set for Jan. 31, 2026.

Daratumumab plus VRd significantly improves survival in newly diagnosed multiple myeloma, supporting its role as a new ...

For example, smoking causes most lung cancers. This provides an opportunity for prevention. With multiple myeloma, few cases are linked to risk factors that can be avoided, so there is no known way to ...